Explore the words cloud of the CHEMCHECK project. It provides you a very rough idea of what is the project "CHEMCHECK" about.
The following table provides information about the project.
STICHTING KATHOLIEKE UNIVERSITEIT
|Coordinator Country||Netherlands [NL]|
|Total cost||1˙500˙000 €|
|EC max contribution||1˙500˙000 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2016-07-01 to 2021-06-30|
Take a look of project's partnership.
|1||STICHTING KATHOLIEKE UNIVERSITEIT||NL (NIJMEGEN)||coordinator||1˙500˙000.00|
Cancer evades the immune system by generating an immunosuppressive tumour-microenvironment through various mechanisms to enable unhampered growth. Recent breakthroughs in blocking one of these mechanisms – the so called ‘immune checkpoints’ – put cancer immunotherapy back in the spotlights. Although promising, clinical benefits of these checkpoint inhibitors as single treatment has been limited to a subset of patients and goes along with unwanted systemic autoimmune toxicity. I hypostasize, that attacking the tumour microenvironment from multiple immunological angles simultaneously by local, conditional, and multimodal immunomodulation will greatly improve success of cancer immunotherapy and patient wellbeing. To achieve this, I will develop a highly defined synergistic chemistry-based molecular therapeutic toolbox to specifically attack cancer, acting on effector T cells, macrophages as well as tumour cells simultaneously. In this highly multidisciplinary endeavour I will (i) generate novel multifunctional dendritic cell targeted anti-cancer vaccines to ‘educate’ the patient’s immune system to recognise the tumour, (ii) I will develop conditional, targeted immune checkpoint inhibitors to release the immunosuppressive break specifically within the tumour microenvironment without the risk of autoimmunity and (iii) I will generate chemical tools to locally eliminate the tumour-associated macrophages to tear down a major immunosuppressive barrier. I will do so utilizing the novel ModimAb technology which I developed to obtain functionalized antibody fragments. These individual therapeutic tools will allow me and my research team to explore uncharted tumour immunological territories in vitro as well as in vivo, greatly advancing the field of cancer immunotherapy. But above all, together they will form a highly dedicated symbiotic immunotherapeutic regime which will be extremely effective without systemic side effects, dramatically improving patient care.
|year||authors and title||journal||last update|
Maksim V. Baranov, Frans Bianchi, Anastasiya Schirmacher, Melissa A.C. van Aart, Sjors Maassen, Elke M. Muntjewerff, Ilse Dingjan, Martin ter Beest, Martijn Verdoes, Samantha G.L. Keyser, Carolyn R. Bertozzi, Ulf Diederichsen, Geert van den Bogaart
The Phosphoinositide Kinase PIKfyve Promotes Cathepsin-S-Mediated Major Histocompatibility Complex Class II Antigen Presentation
published pages: 160-177, ISSN: 2589-0042, DOI: 10.1016/j.isci.2018.12.015
Liping Qiu, Michael Valente, Yusuf Dolen, Eliezer JÃ¤ger, Martin ter Beest, Liyan Zheng, Carl G. Figdor, Martijn Verdoes
Endolysosomal-Escape Nanovaccines through Adjuvant-Induced Tumor Antigen Assembly for Enhanced Effector CD8 + T Cell Activation
published pages: 1703539, ISSN: 1613-6810, DOI: 10.1002/smll.201703539
Bob J. Ignacio, Tyler J. Albin, Aaron P. Esser-Kahn, Martijn Verdoes
Toll-like Receptor Agonist Conjugation: A Chemical Perspective
published pages: 587-603, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00808
|Bioconjugate Chemistry 29/3||2020-02-24|
Floris van Dalen, Marleen van Stevendaal, Felix Fennemann, Martijn Verdoes, Olga Ilina
Molecular Repolarisation of Tumour-Associated Macrophages
published pages: 9, ISSN: 1420-3049, DOI: 10.3390/molecules24010009
Dion Voerman, Marjolein Schluck, Jorieke Weiden, Ben Joosten, Loek J. Eggermont, Tuur van den Eijnde, Bob Ignacio, Alessandra Cambi, Carl G. Figdor, Paul H. J. Kouwer, Martijn Verdoes, Roel Hammink, Alan E. Rowan
Synthetic Semiflexible and Bioactive Brushes
published pages: 2587-2597, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.9b00385
Johan M.S. van der Schoot, Felix L. Fennemann, Michael Valente, Yusuf Dolen, Iris M. Hagemans, Anouk M.D. Becker, Camille M. Le Gall, Duco van Dalen, Alper Cevirgel, J. Armando C. van Bruggen, Melanie Engelfriet, Marieke F. Fransen, Tomislav Caval, Arthur E.H. Bentlage, Maaike Nederend, Jeanette H.W. Leusen, Albert J.R. Heck, Gestur Vidarsson, Carl G. Figdor, Martijn Verdoes*, Ferenc A. Scheeren
Functional diversification of hybridoma produced antibodies by CRISPR/HDR genomic engineering.
published pages: , ISSN: , DOI: 10.1101/551382
Marjolein Schluck, Roel Hammink, Carl G. Figdor, Martijn Verdoes, Jorieke Weiden
Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.00931
|Frontiers in Immunology 10||2020-02-24|
Felix L. Fennemann, I. Jolanda M. de Vries, Carl G. Figdor, Martijn Verdoes
Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.00824
|Frontiers in Immunology 10||2020-02-24|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHEMCHECK" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CHEMCHECK" are provided by the European Opendata Portal: CORDIS opendata.